Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Ripsman D, Fergusson DA, Montroy J, Auer RC, Huang JW, Dobriyal A, Wesch N, Carrier M, Lalu MM. A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models. Thromb Res 2020;195:103-113. [PMID: 32683148 DOI: 10.1016/j.thromres.2020.07.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 07/03/2020] [Accepted: 07/06/2020] [Indexed: 01/30/2023]

For:	Ripsman D, Fergusson DA, Montroy J, Auer RC, Huang JW, Dobriyal A, Wesch N, Carrier M, Lalu MM. A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models. Thromb Res 2020;195:103-113. [PMID: 32683148 DOI: 10.1016/j.thromres.2020.07.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 07/03/2020] [Accepted: 07/06/2020] [Indexed: 01/30/2023]

Supplementary Information

The online version contains supplementary material available at 10.1007/s12015-021-10164-4.

Collapse

Number

Cited by Other Article(s)

Not Just Anticoagulation—New and Old Applications of Heparin. Molecules 2022;27:molecules27206968. [DOI: 10.3390/molecules27206968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 10/07/2022] [Accepted: 10/12/2022] [Indexed: 11/16/2022] Open

Heparin: An old drug for new clinical applications. Carbohydr Polym 2022;295:119818. [DOI: 10.1016/j.carbpol.2022.119818] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 06/26/2022] [Accepted: 06/28/2022] [Indexed: 12/23/2022]

An in vivo rabbit joint injury model to measure trauma-induced coagulopathy and the effect of timing of administration of ketotifen fumarate on posttraumatic joint contracture. OTA Int 2022;5:e177. [PMID: 35282394 PMCID: PMC8900463 DOI: 10.1097/oi9.0000000000000177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 12/20/2021] [Indexed: 11/30/2022]

Abstract

Objectives:

Using a rabbit in vivo joint injury model, the primary objective of the study was to determine if a relationship exists between earlier time to initiation of ketotifen fumarate (KF) treatment and posttraumatic joint contracture (PTJC) reduction. The secondary objective was to determine if a coagulation response could be detected with serial thrombelastography (TEG) analysis following acute trauma in this model.

Methods:

PTJC of the knee were created in 25 skeletally mature, New Zealand White rabbits. Five groups of 5 animals were studied: a control group that received twice daily subcutaneous injections of normal saline and 4 treatment groups that received twice daily subcutaneous injections of KF (0.5 mg/kg) starting immediately, 1-, 2-, and 4-weeks post-injury. After 8 weeks of immobilization, flexion contractures were measured biomechanically. Serial TEG analysis was performed on the control group animals pre-injury and weekly post-injury.

Results:

The average joint contracture in the Control Group (43.1° ± 16.2°) was higher than all KF treatment groups; however, the differences were not statistically significant. The average joint contracture was lowest in the 2-week post-injury treatment group (29.4° ± 12.1°), although not statistically significant compared to the other treatment groups. Serial TEG analysis demonstrated significantly higher mean maximal amplitude (maximal amplitude = 68.9 ± 1.7 mm; P < .001), alpha-angle (81.9° ± 0.9°; P < .001), and coagulation index (4.5 ± 0.3; P < .001) 1-week post-injury, which normalized to pre-injury values by 5-weeks post-injury.

Conclusions:

The use of the mast cell stabilizer KF within 2 weeks of injury demonstrated a nonsignificant trend towards reducing joint contracture in a rabbit in vivo model of PTJC. TEG and the in vivo rabbit joint injury model may be valuable in future preclinical studies of venous thromboembolism prevention and furthering our understanding of the pathophysiology of posttraumatic hypercoagulability.

Collapse

Binder HM, Maeding N, Wolf M, Cronemberger Andrade A, Vari B, Krisch L, Gomes FG, Blöchl C, Muigg K, Poupardin R, Raninger AM, Heuser T, Obermayer A, Ebner-Peking P, Pleyer L, Greil R, Huber CG, Schallmoser K, Strunk D. Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles. Cells 2021;10:3321. [PMID: 34943829 PMCID: PMC8699161 DOI: 10.3390/cells10123321] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Revised: 11/17/2021] [Accepted: 11/24/2021] [Indexed: 12/15/2022] Open

Affiliation(s)

Heide-Marie Binder Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Nicole Maeding Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Martin Wolf Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
André Cronemberger Andrade Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Balazs Vari Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Linda Krisch Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.) Department of Transfusion Medicine and SCI-TReCS, Paracelsus Medical University (PMU), 5020 Salzburg, Austria;
Fausto Gueths Gomes Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Constantin Blöchl Department of Biosciences, Paris Lodron University, 5020 Salzburg, Austria; (C.B.); (A.O.); (C.G.H.)
Katharina Muigg Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Rodolphe Poupardin Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Anna M. Raninger Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Thomas Heuser Vienna BioCenter Core Facilities GmbH, 1030 Vienna, Austria;
Astrid Obermayer Department of Biosciences, Paris Lodron University, 5020 Salzburg, Austria; (C.B.); (A.O.); (C.G.H.)
Patricia Ebner-Peking Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)
Lisa Pleyer 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria; (L.P.); (R.G.) Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT) and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria
Richard Greil 3rd Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, 5020 Salzburg, Austria; (L.P.); (R.G.) Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT) and Cancer Cluster Salzburg (CCS), 5020 Salzburg, Austria Austrian Group for Medical Tumor Therapy (AGMT) Study Group, 1180 Vienna, Austria
Christian G. Huber Department of Biosciences, Paris Lodron University, 5020 Salzburg, Austria; (C.B.); (A.O.); (C.G.H.)
Katharina Schallmoser Department of Transfusion Medicine and SCI-TReCS, Paracelsus Medical University (PMU), 5020 Salzburg, Austria;
Dirk Strunk Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Cell Therapy Institute, Paracelsus Medical University (PMU), 5020 Salzburg, Austria; (H.-M.B.); (N.M.); (M.W.); (A.C.A.); (B.V.); (L.K.); (F.G.G.); (K.M.); (R.P.); (A.M.R.); (P.E.-P.)

Collapse

Heparin and Derivatives for Advanced Cell Therapies. Int J Mol Sci 2021;22:ijms222112041. [PMID: 34769471 PMCID: PMC8584295 DOI: 10.3390/ijms222112041] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 11/03/2021] [Accepted: 11/05/2021] [Indexed: 12/27/2022] Open

Bailey AJM, Li H, Kirkham AM, Tieu A, Maganti HB, Shorr R, Fergusson DA, Lalu MM, Elomazzen H, Allan DS. MSC-Derived Extracellular Vesicles to Heal Diabetic Wounds: a Systematic Review and Meta-Analysis of Preclinical Animal Studies. Stem Cell Rev Rep 2021;18:968-979. [PMID: 33893619 PMCID: PMC8064883 DOI: 10.1007/s12015-021-10164-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/29/2021] [Indexed: 12/15/2022]

Forest plot demonstrating increased wound closure rates of diabetic wounds receiving genetically modified MSC-EVs that were enriched for specific RNAs. DFO = deferoxamine. Control groups were inactive (no treatment or saline) except for 3 studies which used hydrogels without MSC-EVs as control (Li M 2016; Shi 2017; Tao 2016).

Adrian J M Bailey Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada Stem Cells and Centre for Innovation, Canadian Blood Services, Ottawa, Canada Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Canada
Heidi Li Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
Aidan M Kirkham Stem Cells and Centre for Innovation, Canadian Blood Services, Ottawa, Canada Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Canada
Alvin Tieu Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Canada Regenerative Medicine Programs, Ottawa Hospital Research Institute, Ottawa, Canada Departments of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada
Harinad B Maganti Stem Cells and Centre for Innovation, Canadian Blood Services, Ottawa, Canada Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Canada
Risa Shorr Library and Information Services, The Ottawa Hospital, Ottawa, Canada
Dean A Fergusson Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Canada Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada School of Public Health and Epidemiology, University of Ottawa, Ottawa, Canada
Manoj M Lalu Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Canada Regenerative Medicine Programs, Ottawa Hospital Research Institute, Ottawa, Canada Departments of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada Departments of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, Canada
Heidi Elomazzen Stem Cells and Centre for Innovation, Canadian Blood Services, Ottawa, Canada
David S Allan Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Stem Cells and Centre for Innovation, Canadian Blood Services, Ottawa, Canada. Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Canada. Regenerative Medicine Programs, Ottawa Hospital Research Institute, Ottawa, Canada. Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada. Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, Canada.

Collapse

Abstract

In an era when cancer glycobiology research is exponentially growing, we are witnessing a progressive translation of the major scientific findings to the clinical practice with the overarching aim of improving cancer patients' management. Many mechanistic cell biology studies have demonstrated that heparan sulfate (HS) glycosaminoglycans are key molecules responsible for several molecular and biochemical processes, impacting extracellular matrix properties and cellular functions. HS can interact with a myriad of different ligands, and therefore, hold a pleiotropic role in regulating the activity of important cellular receptors and downstream signalling pathways. The aberrant expression of HS glycan chains in tumours determines main malignant features, such as cancer cell proliferation, angiogenesis, invasion and metastasis. In this review, we devote particular attention to HS biological activities, its expression profile and modulation in cancer. Moreover, we highlight HS clinical potential to improve both diagnosis and prognosis of cancer, either as HS-based biomarkers or as therapeutic targets.

Collapse

Affiliation(s)

Isabel Faria-Ramos Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal; (I.F.-R.); (J.P.); (C.M.); (J.S.-A.); (C.A.R.) Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal
Juliana Poças Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal; (I.F.-R.); (J.P.); (C.M.); (J.S.-A.); (C.A.R.) Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal Molecular Biology Department, Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
Catarina Marques Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal; (I.F.-R.); (J.P.); (C.M.); (J.S.-A.); (C.A.R.) Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal Molecular Biology Department, Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
João Santos-Antunes Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal; (I.F.-R.); (J.P.); (C.M.); (J.S.-A.); (C.A.R.) Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal Pathology Department, Faculdade de Medicina, University of Porto, 4200-319 Porto, Portugal; Gastroenterology Department, Centro Hospitalar S. João, 4200-319 Porto, Portugal
Guilherme Macedo Pathology Department, Faculdade de Medicina, University of Porto, 4200-319 Porto, Portugal; Gastroenterology Department, Centro Hospitalar S. João, 4200-319 Porto, Portugal
Celso A. Reis Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal; (I.F.-R.); (J.P.); (C.M.); (J.S.-A.); (C.A.R.) Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal Molecular Biology Department, Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal Pathology Department, Faculdade de Medicina, University of Porto, 4200-319 Porto, Portugal;
Ana Magalhães Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal; (I.F.-R.); (J.P.); (C.M.); (J.S.-A.); (C.A.R.) Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal

Collapse